A pproximately 990 000 people in the United States were living with HIV infection in 2016. 1 Among infected individuals, it was estimated that approximately 15% were unaware of their status. 2 The incidence of HIV infection in the United
States decreased from about 42 000 in 2011 to 40 000 each year from 2013 to 2016. 3 Screening could identify HIV infection in asymptomatic patients, who could benefit from interventions to reduce risk of AIDS-related clinical events and transmission. In 2013, the US Preventive Services Task Force (USPSTF) recommended that clinicians screen all adolescents and adults aged 15 to 65 years for HIV infection, as well as younger adolescents and older adults at increased risk (A recommendation). 4 This recommendation, which expanded on a previous USPSTF recommendation for risk-based HIV screening, 5 was based on new evidence supporting the effectiveness of earlier vs delayed antiretroviral therapy (ART) for HIV infection and the effectiveness of ART for decreasing transmission risk. 6, 7 This evidence report updates the previous USPSTF HIV screening review in nonpregnant adolescents and adults 6, 7 to inform an updated USPSTF recommendation. It targets gaps identified in the prior review, including direct evidence on the benefits and harms of screening, the yield of screening at different intervals, and longterm harms of currently recommended ART regimens. This review also addresses effects of earlier vs later initiation of ART, focusing on patients with baseline CD4 cell counts greater than 350/mm 3 , given expanded treatment indications for ART. 8 Prenatal HIV screening is addressed in a separate report.
Methods

Scope of the Review
Detailed methods and additional study details are available in the full evidence report at https://www.uspreventiveservices taskforce.org /Page/Document /UpdateSummaryFinal/ human-immunodeficiency-virus-hiv-infection-screening1. Figure 1 shows the analytic framework and key questions (KQs) that guided the review.
Data Sources and Searches
Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews were searched 
Key questions
What are the benefits of screening for HIV infection in asymptomatic, nonpregnant adolescents and adults on mortality, AIDS and opportunistic infections, quality of life, function, and reduced transmission of HIV and other sexually transmitted infections?
1
What are the longer-term harms (≥2 years) associated with currently recommended antiretroviral therapy regimens? 5
What are the effects of initiating antiretroviral therapy in adolescents and adults with chronic HIV infection at a higher vs lower CD4 cell count on mortality, AIDS and opportunistic infections, quality of life, function, and reduced transmission of HIV and other sexually transmitted infections, and harms?
4
What is the yield (number of new diagnoses per tests performed) of screening for HIV infection at different intervals in asymptomatic, nonpregnant adolescents and adults, and how does the screening yield vary in different risk groups? for English-language articles published from 2012 through June 2018 (eMethods 1 in the Supplement). Searches were supplemented by review of reference lists from relevant systematic reviews and prior USPSTF reports. Since June 2018, ongoing surveillance was conducted through article alerts and targeted searches of journals to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and the related USPSTF recommendation. The last surveillance was conducted on January 25, 2019, and identified no eligible studies.
Study Selection
Two investigators independently reviewed titles, abstracts, and fulltext articles using predefined eligibility criteria. Randomized clinical trials (RCTs), cohort studies, and case-control studies of adolescents (13 to <18 years) and adults were eligible for all KQs. Studies that directly evaluated the effects of HIV screening vs no screening in asymptomatic individuals on clinical outcomes (mortality, AIDS and opportunistic infections, quality of life, function, HIV transmission, and harms) were eligible for KQ1 and KQ3. Studies that evaluated the yield (number of new diagnoses per tests performed) of screening for HIV infection at different intervals or in different risk groups were eligible for KQ2. Studies that compared effects of initiating ART at higher vs lower CD4 cell count on clinical outcomes were eligible for KQ4; observational studies had to enroll at least 1000 patients. Studies that evaluated longer-term (Ն2 years) harms associated with currently recommended ART regimens were eligible for KQ5. This update focused on studies conducted in the United States and other settings with similar prevalence and management of HIV infection, unless such studies were not available.
Data Abstraction and Quality Rating
For each study, one investigator abstracted information on populations, interventions or screening instruments, comparators, adherence, outcomes, study designs, and settings. A second investigator reviewed abstracted information for accuracy. Randomized trials of early vs delayed ART primarily reported outcomes using hazard ratios. Relative risks (RRs) were calculated based on reported event rates, to calculate absolute risk differences (ARDs). RRs and hazard ratios were very similar, and reported results are based on RRs. Two independent investigators assessed the quality of each study as good, fair, or poor using predefined criteria developed by the USPSTF (eMethods 2 in the Supplement). Individual study quality ratings are provided in eTables 1-6 in the Supplement.
Data Synthesis
Results were summarized qualitatively. Meta-analysis was not performed because of clinical and methodological heterogeneity among studies. For all KQs, the overall strength of the body of evidence was assessed as high, moderate, low, or insufficient using methods developed by the USPSTF, based on the overall quality of studies, consistency of results between studies, precision of findings, and risk of reporting bias. 10 The applicability of the findings to US primary care populations and settings was also assessed.
Results
Two reviewers independently assessed 4882 unique citations and 348 full-text articles for inclusion ( Figure 2) . Eighteen new studies (5 RCTs, 11-17 11 cohort studies, 18-37 and 2 systematic reviews 38, 39 ; 29 articles; N = 266 563) were included, and 11 studies (2 RCTs 40,41 and 9 cohort studies [42] [43] [44] [45] [46] [47] [48] [49] [50] ; N =218 542) were carried forward from the prior USPSTF report. ( Table 2) . 21 However, the confidence intervals for the risk estimates overlapped and there was no test for statistical significance for the difference.
Harms of Immediate vs Delayed ART
Two RCTs (n = 4950) found no evidence of an increased risk of cardiovascular events with early vs delayed ART, although data were limited by small numbers of events (eTable 8 in the Supplement).
13,41
The START, HPTN 052, and TEMPRANO ANRS 12136 trials also found no significant differences between early vs delayed initiation of ART and risk of other harms, such as liver disease, renal disease, and newonset diabetes. 12,13,15 Few adverse events were reported and some risk estimates were imprecise.
Longer-Term Harms of Treatment
Key Question 5. What are the longer-term harms (Ն2 years) associated with currently recommended ART regimens?
The prior USPSTF report focused on longer-term cardiovascular harms of ART.
6,7 Details on evidence reviewed for this update on longer-term cardiovascular and additional harms are reported in eTables 11-13 in the Supplement.
Cardiovascular Events
The prior USPSTF report found mixed evidence on the risk of longterm cardiovascular events with abacavir use based on 4 cohort studies, including the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) observational study, 47- 30 Other observational studies (n = 34 487) also found tenofovir and protease inhibitors associated with increased risk of renal adverse events.
29,31,33
Fracture A cohort study (n = 11 820) found ever using tenofovir associated with increased risk of fracture (incidence rate ratio, 1.40 [95% CI, 1.15 to 1.70]) but no association between cumulative exposure to tenofovir and risk of fracture (incidence rate ratio per 5 years of exposure, 1.08 [95% CI, 0.94 to 1.25]).
36
Non-AIDS Mortality
An analysis of a European cohort (EuroSIDA [n = 12 069]) found no association between longer-term (>2 years) exposure to ART and risk of non-AIDS-related deaths after a median of 5.4 years.
Discussion
As in previous USPSTF reviews on this topic, 7,52 there remains no direct evidence on clinical benefits and harms of screening for HIV infection vs no screening or the yield of repeat or alternative screening strategies. Table 3 summarizes the other evidence reviewed in this update. New data extend evidence on effectiveness of ART to people with CD4 cell counts greater than 500/mm, 3, 13, 15, 19 expanding on previous findings 7 of a strong association between initiation of ART at CD4 cell counts of 350/mm 3 to 500/mm 3 or 550/mm 3 and reduced risk of death or AIDS-related illness and substantially reduced risk of sexual transmission of HIV infection, compared with initiation at lower CD4 cell counts. New data also found effects of ART initiation at CD4 cell counts greater than 350/mm 3 were sustained. 11,12 Other systematic reviews on timing of ART found insufficient evidence to determine effects of initiation of ART at CD4 cell counts greater than 500/mm No clinical study evaluated the yield of repeat vs 1-time screening or of screening at different intervals. Modeling studies suggest that repeat screening as frequently as once every 3 months may be cost-effective in high-risk individuals, depending on testing 
Limitations
This review had several limitations. First, inclusion was restricted to English-language articles, although no non-English-language studies that would have met inclusion criteria were identified. Second, it was not possible to formally assess for publication bias with graphical or statistical methods because of small numbers of studies; however, eligible unpublished trials were not identified in searches on ClinicalTrials.gov. Third, observational studies, which are susceptible to bias and confounding, were included, although results focused on studies that performed statistical adjustment for potential confounding. Fourth, some studies were conducted in resource-poor and high-prevalence settings, which could reduce applicability to US practice. Fifth, studies of long-term harms of ART often did not specify the regimen used or analyze effects of specific antiretroviral drugs rather than the regimen as a whole, some evidence on long-term harms of ART apply to drugs not considered first-line options, and analyses have difficulty in accounting for ART regimen switches.
Conclusions
In nonpregnant adolescents and adults there was no direct evidence on the clinical benefits and harms of screening for HIV infections vs no screening, or the yield of repeat or alternative screening strategies. New evidence extends effectiveness of ART to asymptomatic individuals with CD4 cell counts greater than 500/mm 3 and
shows sustained reduction in risk of HIV transmission at longerterm follow-up, although certain ART regimens may be associated with increased risk of long-term harms.
